Despite the clear therapeutic potential for ARH3 and PARG as drug targets and biomarkers for cancer cell sensitivity to PARP and PARG inhibition, implementation of these strategies in clinics currently faces significant challenges. The gene discussed is ADPRS; the disease is cancer.